AASLD 2021
Nov 14
Nov 15
of AASLD
AASLD 2021
S2-E53 – SurfingNASH Previews AASLD 2021: The Digital Liver Meeting
Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss key presentations at AASLD 2021 and preview SurfingNASH’s coverage of the event. This virtual meeting runs from November 12-15 and is scheduled on East Coast time. MORE >Nov 14
Coverage of
Sunday, Nov 14, 2021
Our Surfers Discussed The Following Papers and Sessions on Day 3
Roger Green — Presidential Plenary
Presidential Plenary Topline Results from ALPINE 2/3 Study — Harrison
— Late-breaker 1
FALCON 1/2 — Loomba
Louise Campbell MSc AP — Parallel 2
An advanced practice provider (APP) pathway achieves more effective weight loss in NAFLD patients compared to standards of care — Shah
Naim Alkhouri — Parallel 5
The Prevalence of Alcoholic and Nonalcoholic Fatty Liver Disease in Adolescents and Young Adults in the US — Alkhouri.
Scott L. Friedman, MD — Poster 1781
Gut microbial factors activated intrahepatic B cells to promote non-alcoholic steatohepatitis via innate and adaptive signaling — Barrow
Michelle Long, MD — Presidential Plenary
Longitudinal association between MRE and liver-related events and CV events in NAFLD — Tamaki
Jeff McIntyre — Patient
Grit, Grace, Gratitude and Resilience: What You Wish Your Doctors Knew about You — Cryer
— Poster 1654
The influence of host genetics on liver microbiome composition in patients with NAFLD — Sookoian
Surfing The NASH Tsunami Podcast Day 3
Nov 15
Coverage of
Monday, Nov 15, 2021
Our Surfers Discussed The Following Papers and Sessions on Day 4
Roger Green — Trend: Tailoring NASH Therapy
Subtyping NAFLD by Non-invasive testing — Allen
— Parallel 17
MVX predicts the risk of mortality and liver outcomes in NAFLD; or Utiliation of the MAST score to predict NASH on biopsy in MAESTRO-NASH and assess respone to resmetirom in MAESTRO NAFLD-1 — Sanyal or Noureddin
Louise Campbell MSc AP — Parallel 29
Impact of modest weight reduction on serum markets, liver histology and disease progression in patients with advanced fibrosis due to NASH — Bosch
— Late-breaker 1
Burden of Illness and economic impact of NASH in the US according to the presence of obesity — Younossi
Stephen Harrison — Late-breaker 1
Vonafexor, a FXR Agonist, induced hepatic and renal improvement in the randomized, double-blind, placebo-controlled LIVIFY NASH trial — Harrison.
— Parallel 36 — Reduction in liver fast content with HTD1801 (Berberine ursodeoxycholate) is closely associated with improved glycemic control, weight loss and reduced ALT — Harrison.
Mazen Noureddin MD MHSc — Late-breaker 1
Primar results of the NIMBLE Stage 1-NASH CRN study of circulating biomarkers for NASH and its activity and fibrosis stage — Sanyal
— Late-breaker 1
PROXYMO demonstrates the safety and efficacy of cotadutide, a novel incretin co-agonist in biopsy-proven non-cirrhotic NASH with fibrosis — Sanyal
Jeff McIntyre — Poster 1741
The burden of NAFLD is rapidly growing in every region of the world — Paik
— Trend: Tailoring NASH Therapy
Lifestyle Management of NAFLD with Obesity — Corey
Michael Charlton — Late Breaker 1
Efficacy and Safety of Pegbelfermin in Patient with NASH and Stage 3 Fibrosis: Results from the Phase 2b FALCON 1 study
Surfing The NASH Tsunami Podcast Day 4
of AASLD
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap this week’s just-concluded TLMdX 2021, the AASLD annual liver meeting. MORE >
Available In Your Favorite Podcast App:
